NO20033443L - Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser - Google Patents

Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser

Info

Publication number
NO20033443L
NO20033443L NO20033443A NO20033443A NO20033443L NO 20033443 L NO20033443 L NO 20033443L NO 20033443 A NO20033443 A NO 20033443A NO 20033443 A NO20033443 A NO 20033443A NO 20033443 L NO20033443 L NO 20033443L
Authority
NO
Norway
Prior art keywords
prevention
treatment
binding agents
skin disorders
disorders
Prior art date
Application number
NO20033443A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033443D0 (no
Inventor
Akshay K Vaishnaw
Kevin D Cooper
Daniel Shrager
Thomas S Mccormick
Original Assignee
Univ Cleveland Hospitals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cleveland Hospitals filed Critical Univ Cleveland Hospitals
Publication of NO20033443D0 publication Critical patent/NO20033443D0/no
Publication of NO20033443L publication Critical patent/NO20033443L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20033443A 2001-02-01 2003-08-01 Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser NO20033443L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26596401P 2001-02-01 2001-02-01
PCT/US2002/002314 WO2002060480A1 (en) 2001-02-01 2002-01-25 Methods for treating or preventing skin disorders using cd2-binding agents

Publications (2)

Publication Number Publication Date
NO20033443D0 NO20033443D0 (no) 2003-08-01
NO20033443L true NO20033443L (no) 2003-09-30

Family

ID=23012611

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033443A NO20033443L (no) 2001-02-01 2003-08-01 Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser

Country Status (22)

Country Link
US (3) US20040170635A1 (de)
EP (1) EP1409015A4 (de)
JP (1) JP2004527477A (de)
KR (1) KR20040043112A (de)
CN (1) CN1527723A (de)
AR (1) AR035079A1 (de)
BG (1) BG108020A (de)
BR (1) BR0206905A (de)
CA (1) CA2436411A1 (de)
CZ (1) CZ20032081A3 (de)
EA (1) EA200300849A1 (de)
EE (1) EE200300366A (de)
GE (1) GEP20063828B (de)
HU (1) HUP0303826A2 (de)
IS (1) IS6894A (de)
MX (1) MXPA03006919A (de)
NO (1) NO20033443L (de)
PL (1) PL368556A1 (de)
SK (1) SK9722003A3 (de)
WO (1) WO2002060480A1 (de)
YU (1) YU61203A (de)
ZA (1) ZA200305936B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP1109570B1 (de) * 1998-08-31 2005-10-19 Biogen, Inc. Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
CA2454618C (en) 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
DK1556020T3 (da) 2002-08-12 2009-06-22 Birkir Sveinsson Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20070172478A1 (en) * 2004-02-06 2007-07-26 Astellas Us Llc Methods of treating skin disorders
BRPI0510691A (pt) * 2004-05-04 2007-12-26 Genaissance Pharmaceuticals marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
US9289469B2 (en) 2009-09-10 2016-03-22 Mayo Foundation For Medical Education And Research Depleting immunosuppressive monocytes within a mammal
US9266957B2 (en) 2009-11-10 2016-02-23 Mayo Foundation For Medical Education And Research Methods and materials for treating renal cell carcinoma and glioblastoma multiforme
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
US9970936B2 (en) 2012-11-13 2018-05-15 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
WO2014182761A1 (en) 2013-05-09 2014-11-13 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
AU2019242451B2 (en) * 2018-03-29 2024-05-09 Pfizer Inc. LFA3 variants and compositions and uses thereof
WO2023224980A1 (en) * 2022-05-17 2023-11-23 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
WO2024050455A2 (en) * 2022-08-31 2024-03-07 Heitmeyer Jamie Nicole Anti-rhd antibodies for treating inflammatory dermal condition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2112335T3 (es) * 1991-10-07 1998-04-01 Biogen Inc Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3.
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
EP1109570B1 (de) * 1998-08-31 2005-10-19 Biogen, Inc. Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes

Also Published As

Publication number Publication date
WO2002060480A9 (en) 2004-05-27
YU61203A (sh) 2006-05-25
CA2436411A1 (en) 2002-08-08
AR035079A1 (es) 2004-04-14
IS6894A (is) 2003-07-25
EP1409015A1 (de) 2004-04-21
EE200300366A (et) 2003-12-15
JP2004527477A (ja) 2004-09-09
EA200300849A1 (ru) 2004-02-26
SK9722003A3 (en) 2004-05-04
BG108020A (bg) 2004-03-31
US20070031443A1 (en) 2007-02-08
ZA200305936B (en) 2005-01-26
CZ20032081A3 (cs) 2004-01-14
MXPA03006919A (es) 2004-06-02
US20040170635A1 (en) 2004-09-02
GEP20063828B (en) 2006-05-10
PL368556A1 (en) 2005-04-04
CN1527723A (zh) 2004-09-08
US20030185824A1 (en) 2003-10-02
WO2002060480A1 (en) 2002-08-08
HUP0303826A2 (hu) 2004-03-01
BR0206905A (pt) 2004-07-06
KR20040043112A (ko) 2004-05-22
NO20033443D0 (no) 2003-08-01
EP1409015A4 (de) 2006-04-12

Similar Documents

Publication Publication Date Title
NO20033443D0 (no) Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser
NO20041588L (no) Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
BR0211251B1 (pt) composição para o tratamento de cabelo e/ou couro cabeludo.
EP1455778A4 (de) Verfahren zur behandlung von peripheren nerven- und gefässerkrankungen
NO20022680L (no) Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
EP1392292A4 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
NO20052699D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
NO20033803L (no) Karbamatforbindelser for anvendelse ved prevensjon eller terapi av bevegelseslidelser
NO20033798L (no) Karbamatforbindelser for bruk ved prevensjon eller terapi av neurodegenerative lidelser
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
NO20040659L (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
EP1406648A4 (de) Verwendung von angiotensin-i-derivat als mittel zur behandlung und verhütung von infarktbedingten herzschäden und erkrankungen
PT1381620E (pt) Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
EP1539100A4 (de) Zusammensetzung und verfahren zur behandlung von hauterkrankungen
HUP0204209A3 (en) Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms